The Prostate Health Podcast
Browse all of the episodes below!
99: Key Takeaways: Society of Benign Prostate Disease 2024 Annual Meeting – Kevin C. Zorn, MD, FRCSC, FACS
Today, I am delighted to have one of the Society of Benign Prostate Disease board of directors, Dr. Kevin Zorn, joining me to share an insider perspective as we review the key takeaways from the meeting and bring you up to speed on the latest technologies for evaluating and managing BPH. We will also offer a sneak peek into several new advancements coming down the pipeline.
Dr. Kevin Zorn, from the BPH Canada Clinic in Montreal, is a board-certified neurologist and former Associate Professor of Urology at the Universities of Montreal and Chicago, sub-specializing in robotic surgery and BPH surgical care. Throughout his career, Dr. Zorn has been committed to research and innovation. He was the first in Canada and Quebec to use many new BPH technologies, including Greenlight XPS, Rezum, ITind, Optilume, and aquablation.
Dr. Zorn is a senior author of the BPH guidelines for the Canadian Urological Association, having authored 345 peer-reviewed publications and 12 book chapters on BPH and minimally invasive surgical care. He has lectured, taught, and practiced surgery globally and is intimately involved in developing several new pioneering BPH technologies.
Stay tuned for the latest insights and breakthroughs as we unveil the future of BPH management.
Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation.
98: Biodegradable Balloon System to Revolutionize Rectal Protection During Prostate Cancer Radiation Therapy – Jonathan D. Tward, MD, PhD
Weighing the possible side effects of prostate cancer treatments while considering various treatment options can be a daunting challenge for men and their loved ones.
We are excited to partner with BioProtect for this episode, with our distinguished guest, Dr. Jonathan Tward, a Radiation Oncologist and tenured professor in the Department of Radiation Oncology at the University of Utah Health. Dr. Tward will fill us in on a progressive new technology that aims to minimize both short and long-term side effects of radiation therapy for prostate cancer.
Dr. Tward is a highly regarded authority and key opinion leader in the management of prostate cancer. He earned a Ph.D. in biochemistry at UCLA, a Medical Degree at Tufts University in Boston, and he completed his radiation oncology residency training at the University of Utah. He holds the Vincent P. and Janet Manzini Presidential Endowed Chair at Huntsman Cancer Institute in genitourinary malignancies.
Dr. Tward specializes in delivering precisely targeted radiation therapy for numerous genitourinary malignancies, including prostate cancer. He utilizes various advanced technologies, including intensity-modulated radiotherapy, image-guided radiotherapy, stereotactic body radiotherapy, and low and high-dose-rate brachytherapy. Dr. Tward has contributed to over 100 published peer-reviewed journal articles. He also actively serves on the National Comprehensive Cancer Network clinical practice guidelines committees for prostate, bladder, and penile cancers.
Join us today for an exclusive dive into the latest cutting-edge solution for reducing the impact of radiation therapy’s side effects on prostate cancer patients.
97: Men’s Health and Hormone Optimization – Amy Pearlman, MD and Michelle Pearlman, MD
Low testosterone is a burning issue. It remains a widely debated topic and is a common dilemma for men, especially as they age.
We are thrilled to get the ball rolling for the 2024 Prostate Health Podcast season with two fantastic guests to discuss strategies for hormonal optimization.
Doctors Amy and Michelle Pearlman are sisters. Dr. Amy Pearlman is a certified neurologist specializing in male sexual and hormonal health and genital reconstruction. She did her urology residency at the University of Pennsylvania and her fellowship training in urologic reconstruction, prosthetic urology, and infertility at Wake Forest University. Even though she trained as a surgeon, her primary mission lies in educating individuals about fundamental aspects of their bodies to foster health-conscious behaviors, optimize their health, and support them in living their most authentic lives.
Dr. Michelle Pearlman is a board-certified gastroenterologist and obesity medicine specialist. She did her residency training at the University of California San Diego and a gastroenterology fellowship at the University of Texas Southwestern in Dallas. As a board-certified gastroenterologist, she understands the significance of maintaining gut health concerning dietary habits and sustaining a healthy weight.
This dynamic sibling duo brings a wealth of knowledge to our podcast, shedding light on both urology and gastroenterology perspectives for a holistic approach to well-being and offering valuable insights into hormonal optimization.
Whether you are navigating the challenges of low testosterone or simply seeking ways to live your best life in 2024 and beyond, this episode is a must-listen. Stay tuned for valuable insights to enhance your health in the new year!
96: Advancing Precision Medicine: EpiSwitch PSE Prostate Cancer Screening Test with 94% Accuracy – Robert Heaton, MD
Did you know that prostate cancer is the second most prevalent cancer in American men, following skin cancer? A new diagnosis of prostate cancer occurs every two minutes.
We are delighted to partner with Oxford Biodynamics for today’s episode with Dr. Robert Heaton, who joins us to discuss a ground-breaking new prostate cancer screening test that predicts the risk of prostate cancer with 94% accuracy, using a simple blood test.
Dr. Heaton is a board-certified pathologist. He completed his medical training at Georgetown University and then spent the next twenty years in the US Navy. After finishing his residency training in pathology, Dr. Heaton became the Director of Laboratory and Clinical Support Services for the National Naval Medical Center before joining various hospital pathology labs and life sciences companies. He is currently the Laboratory Medical Director for Oxford Biodynamics at their CLIA-certified clinical lab in Maryland, where he oversees the clinical operations of their liquid biopsy blood tests.
In today’s episode, we dive into the details of the innovative EpiSwitch Prostate Screening test, known as the PSE, designed to confirm the presence of prostate cancer, whether symptoms are present or not. This technological advancement is a game-changer! It empowers urologists by providing a precise tool to assess whether a patient should undergo a biopsy or opt for continued monitoring.
Stay tuned to learn how this simple yet powerful tool streamlines the screening process for men struggling with prostate cancer.
95: Initial Experience with the In-Office Promaxo MRI System: Identifying and Targeting Prostate Cancer
Within the ever-evolving landscape of medical technology, breakthrough innovations continuously emerge to revolutionize how urologists approach the detection and treatment of prostate cancer.
In this episode, we dive into Dr. Pohlman’s first-hand encounter with the state-of-the-art Promaxo MRI system that has transformed his practice since June.
On the patient side, we unravel the inner workings of the Promaxo MRI technology, explaining how the system benefits men going through a prostate biopsy. For urologists listening, we explore the practicalities of how Dr. Pohlman integrated the Promaxo MRI system into an office setting, covering the minimal facility prerequisites and describing how the system synced with the general workflow of his clinic. We also get into how Dr. Pohlman is gearing up to begin using the Promaxo MRI system for performing in-office targeted focal ablation for prostate cancer and we also share crucial considerations for urologists to bear in mind when performing low-field MRIs on patients with implants.
Stay tuned for a transformative journey through the world of cutting-edge medical technology!
94: Targeted Focal Laser Ablation for Prostate Cancer – Michael Magnani
We are delighted to team up with Clinical Laserthermia Systems Americas this week for a groundbreaking episode where we dive into the world of cutting-edge medical technology and shed light on an emerging innovation that promises to revolutionize the management of prostate cancer!
CLS is a leading medical device company at the forefront of pioneering precise and effective interventional healthcare solutions. They have developed an innovative CLS thermal therapy system for image-guided focal laser ablation that spares healthy tissue while minimizing the debilitating side effects often associated with traditional treatments. This technology can even be administered by a urologist in an office setting, bringing hope and convenience to countless patients.
We are honored to have Michael Magnani, the President of CLS, joining us today to explore their new thermal therapy system for image-guided focal laser ablation. With a career spanning over two decades in corporate management within the life sciences industry, he brings a wealth of expertise in product development, corporate strategy, business development, and commercialization. He graduated from the unique Biomedical Enterprise Program at the MIT Sloan School of Management and holds a Bachelor of Science in Microbiology from the University of California, San Diego.
Join us to learn about the exciting possibilities this transformative new technology holds for the future of prostate cancer management!
Better Prostate Education is our Mission!
Subscribe to the show on any of these podcast apps